Aadi Bioscience Ownership
| AADI Stock | USD 2.98 0.15 4.79% |
Shares in Circulation | First Issued 2017-06-30 | Previous Quarter 27 M | Current Value 27 M | Avarage Shares Outstanding 11.3 M | Quarterly Volatility 10.9 M |
Aadi |
Aadi Stock Ownership Analysis
About 52.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.07. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aadi Bioscience recorded a loss per share of 2.28. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 27th of August 2021. Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. Aadi Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people. For more info on Aadi Bioscience please contact David Lennon at 424 744 8055 or go to https://aadibio.com.Aadi Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aadi Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aadi Bioscience backward and forwards among themselves. Aadi Bioscience's institutional investor refers to the entity that pools money to purchase Aadi Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-09-30 | 93.3 K | Susquehanna International Group, Llp | 2024-09-30 | 71.9 K | State Street Corp | 2024-09-30 | 68.7 K | Northern Trust Corp | 2024-09-30 | 68.5 K | Marquette Asset Management Inc. | 2024-09-30 | 63.6 K | Ubs Group Ag | 2024-09-30 | 50.7 K | Affinity Asset Advisors, Llc | 2024-09-30 | 47 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 41.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 35.6 K | Venbio Select Advisor Llc | 2024-09-30 | 2.8 M | Bml Capital Management Llc | 2024-09-30 | 2 M |
Aadi Bioscience Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aadi Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aadi Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aadi Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aadi Bioscience Outstanding Bonds
Aadi Bioscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aadi Bioscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aadi bonds can be classified according to their maturity, which is the date when Aadi Bioscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| International Game Technology Corp BondUS460599AD57 | View | |
| ABB FIN USA Corp BondUS00037BAC63 | View | |
| ABB FIN USA Corp BondUS00037BAF94 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Aadi Bioscience Corporate Filings
| 31st of December 2024 Other Reports | ViewVerify | |
| 30th of December 2024 Other Reports | ViewVerify | |
| 23rd of December 2024 Other Reports | ViewVerify | |
8K | 20th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aadi Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Aadi Stock please use our How to Invest in Aadi Bioscience guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aadi Bioscience. If investors know Aadi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aadi Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share | Quarterly Revenue Growth 0.21 | Return On Assets | Return On Equity |
The market value of Aadi Bioscience is measured differently than its book value, which is the value of Aadi that is recorded on the company's balance sheet. Investors also form their own opinion of Aadi Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Aadi Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aadi Bioscience's market value can be influenced by many factors that don't directly affect Aadi Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aadi Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aadi Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aadi Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.